BRM-Targeting Small-Molecule Compounds for BRG1-Deficient Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments targeting BRM, particularly for BRG1-related or BRG1-deficient cancers such as lung cancer, as BRM is essential for compensating BRG1 deficiency in cancer cell lines, leading to synthetic lethality that can be leveraged for therapeutic intervention.
Innovation Solution
Development of compounds that modulate BRM activity, specifically small-molecule therapeutic agents targeting BRM to inhibit or degrade it, thereby treating BRM-mediated disorders including BRG1-related cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRM is targeted for inhibition or degradation in BRG1-related cancers, then therapeutic efficacy is improved through synthetic lethality, but the complexity of developing and validating such targeted therapies increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of small-molecule compounds to optimize their binding affinity and selectivity for BRM. By adjusting molecular parameters such as heterocyclic substitutions and functional groups, the compounds achieve enhanced therapeutic efficacy while maintaining manageable development complexity through systematic structure-activity relationship optimization.
2Reliability
If small-molecule therapeutic agents are developed to target BRM, then treatment effectiveness for BRG1-related cancers is improved, but the manufacturing and validation processes become more complex
Solution Approach 1:
The patent employs segmentation by dividing the BRM target into specific binding sites and functional domains, allowing the small-molecule compounds to be designed with modular structures that target specific regions. This segmentation enables systematic optimization of manufacturing processes and validation protocols, improving treatment effectiveness while maintaining ease of production through standardized synthetic pathways.
Data Source
AI summary
The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.